Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd

Primary objective: To evaluate the safety and tolerability of multiple-dose NVS451 fusion protein for injection in patients with moderate to severe plaque psoriasis and determine the MTD. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of multiple-dose NVS451 fusion protein for injection in patients with moderate to severe plaque psoriasis; To evaluate the pharmacodynamic (PD) characteristics of multiple-dose NVS451 fusion protein for injection in patients with moderate to severe plaque psoriasis; To evaluate the immunogenicity of multiple-dose NVS451 fusion protein for injection in patients with moderate to severe plaque psoriasis. Exploratory objective: To evaluate the preliminary clinical efficacy of multiple-dose NVS451 fusion protein for injection in patients with moderate to severe plaque psoriasis.

Primary objective: To evaluate the safety and tolerability of a single subcutaneous injection of NVS451 fusion protein for injection in healthy subjects; Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of NVS451 fusion protein for injection in healthy subjects; To evaluate the immunogenicity of a single subcutaneous injection of NVS451 fusion protein for injection in healthy subjects; Exploratory objective: To explore biomarkers of a single subcutaneous injection of NVS451 fusion protein for injection in healthy subjects.

To evaluate the safety of adsorbed acellular diphtheria, pertussis and tetanus combined with inactivated poliomyelitis vaccine in infants aged 2 to 24 months and children aged 4 to 6 years; to explore the immunogenicity of adsorbed acellular diphtheria, pertussis and tetanus combined with inactivated poliomyelitis vaccine